Xeureka Held the First Executive Board Meeting of Tokyo-1

On March 4, 2024, the first Executive Board meeting of Tokyo-1 was held at the headquarters of Mitsui & Co.. Executives from Astellas Pharma, Ono Pharmaceutical, Daiichi Sankyo, and NVIDIA participated in the event, where an active exchange of opinions took place.
During the event, the latest global trends were discussed, including the development of large-scale AI drug discovery infrastructure by and collaborations between overseas pharmaceutical and AI drug discovery companies, collaborations with other companies, as well as examples of organizational development and talent acquisition. Additionally, the discussion touched upon what domestic pharmaceutical companies should aim to achieve through Tokyo-1. As a result, this provided the opportunity for a lively exchange of opinions regarding the direction that drug discovery in Japan should take.
Furthermore, the pharmaceutical company executives expressed strong expectations for Tokyo-1 to serve as an innovation hub to drive real innovation. They highlighted the importance of collaboration in non-competitive areas, such as the joint validation of new technologies within the regular Tokyo-1 community activites held multiple times per month, and voiced their enthusiasm for the potential of Tokyo-1.
The Executive Board is scheduled to meet regularly every six months. At the next meeting, further global trends will be discussed, and pharmaceutical companies will present the initial results from their use of Tokyo-1.
Leveraging the ideas generated through the exchange of opinions among the executive members, Tokyo-1 will aim to become a leading innovation hub within the Japanese healthcare industry, with an initial focus on drug discovery.